Epstein Files Search

EFTA01092032Set 9

25p12,760w

Lonw (LONN.VX)- CHF72.30 -NR investors have been asking if there are implications for other Mesoblast Ltd. (MBLTY)- $25.14 - Buy allogeneic companies. NeoStem closed its presentation at the NeoStem, Inc. (A1B5 ... want to raise the allo safety question. We spoke with Athersys and Mesoblast (allogeneic cells), and both companies told us 0 A4.110/0130110 morneic that they have had zero immune-related ... delivered doses of more than 1 billion cells systemically with no reported immune reactions. Mesoblast has tested its products in hundreds of patients with no alto-related AEs. The only

https://www.justice.gov/epstein/files/DataSet%209/EFTA01092032.pdf

EFTA00956529Set 9

2013-03-147p5,347w

national. tem Inc. - 7he LiTe Sciences TLSR: I know you follow Melbourne. Australia-based Mesoblast Ltd. (MSB:ASE: MBLTY:OTCPK). a Reportnierview with Pacific Rim company. Tell me about ... stem cell business development It was no accident that Dr. Silviu Itescu founded Mesoblast in Austraka. It was Dr. Itesais goal to avoid some of the problems that micro ... think of companies as global. That's powerhouse." very much in evidence with Mesoblast. in that it's moving forward with a global. 1.700-patient congestive heart failure (CHF) trial

https://www.justice.gov/epstein/files/DataSet%209/EFTA00956529.pdf

EFTA01092027Set 9

2013-10-125p2,524w

treat chronic NR wounds, under FDA regulatory pathway 21 C.F.R. Part 1271. We Mesoblast (MBLTY) - $29.25 - Buy examined this regulatory pathway (in ow 8/16/2013 report), trying Osiris (OSIR ... written, they will meet the first criterion. On the other hand, Athersys' MAPC, Mesoblast's mesenchymal precursor cells (MPC), or Pluristem's Placental eXpanded (PLX) cells will not meet this

https://www.justice.gov/epstein/files/DataSet%209/EFTA01092027.pdf

EFTA01092057Set 9

2013-08-165p2,594w

Dendreon (DNDN) - $3.15 - Sell IntelliCell Biosciences (SVFC) - $0.02 — NR Lonw (LONIV.VX)- CHF69.50 - NR Mesoblast Ltd. (MBLTY) - $26.95 - Buy Unlocking a Rich commercial Pathway through a backdoor? NeoStem ... written they will meet the first criterion. On the other hand, Athersys MAPC, Mesoblasts Messenchymal precursor cells (MPC) or Pluristem's Placental eXpanded (PLX) cells will not meet this requirement

https://www.justice.gov/epstein/files/DataSet%209/EFTA01092057.pdf